Article info

Download PDFPDF

JAK inhibitors and COVID-19

Authors

  • Gabriel Levy Signal Transduction and Molecular Hematology, Ludwig Institute for Cancer Research, Brussels, BelgiumSignal Transduction on Molecular Hematology, de Duve Institute, Université Catholique de Louvain, Bruxelles, BelgiumWELBIO, Walloon Excellence in Life Sciences and Biotechnology, Brussels, Belgium PubMed articlesGoogle scholar articles
  • Paola Guglielmelli Department of Clinical and Experimental Medicine, University of Florence, Firenze, ItalyCenter of Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Firenze, Italy PubMed articlesGoogle scholar articles
  • Peter Langmuir Oncology Targeted Therapeutics, Incyte Corp, Wilmington, Delaware, USA PubMed articlesGoogle scholar articles
  • Stefan Constantinescu Signal Transduction and Molecular Hematology, Ludwig Institute for Cancer Research, Brussels, BelgiumSignal Transduction on Molecular Hematology, de Duve Institute, Université Catholique de Louvain, Bruxelles, BelgiumWELBIO, Walloon Excellence in Life Sciences and Biotechnology, Brussels, BelgiumNuffield Department of Medicine, Oxford University, Ludwig Institute for Cancer Research, Oxford, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Stefan Constantinescu; stefan.constantinescu{at}uclouvain.be
View Full Text

Citation

Levy G, Guglielmelli P, Langmuir P, et al
JAK inhibitors and COVID-19

Publication history

  • Accepted March 28, 2022
  • First published April 22, 2022.
Online issue publication 
April 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.